Related Experiment Videos

The neurologic complications of B-cell chronic lymphocytic leukemia

J H Bower1, J E Hammack, S K McDonnell

  • 1Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.

Neurology
|February 1, 1997
PubMed

Insights

Neurologic complications in B-cell chronic lymphocytic leukemia (B-CLL) are uncommon, with herpes zoster being the most frequent. Disease stage significantly impacts the risk of these complications.

Area of Science:

  • Neurology
  • Hematology
  • Oncology

Background:

  • B-cell chronic lymphocytic leukemia (B-CLL) is a common B-cell malignancy.
  • Neurologic complications can affect patients with B-CLL, impacting quality of life and prognosis.
  • Understanding the spectrum and risk factors for these complications is crucial for patient management.

Purpose of the Study:

  • To characterize the types, frequency, and timing of neurologic complications in B-CLL patients.
  • To identify correlations between B-CLL stage and the occurrence of neurologic complications.
  • To provide insights into the risk stratification for neurologic events in B-CLL.

Main Methods:

  • Retrospective chart review of 962 patients diagnosed with B-cell chronic lymphocytic leukemia.
  • Analysis of neurologic complication types, including infections, treatment-related events, and direct leukemic involvement.
  • Evaluation of complication occurrence in relation to disease stage (Rai staging) and time from diagnosis.

Main Results:

  • A total of 109 neurologic complications (11.3%) were identified in 962 patients.
  • Herpes zoster infection was the most common complication (7.2%), followed by other opportunistic infections (1.8%) and treatment-related conditions (1.5%).
  • Early-stage B-CLL (Rai 0-2) showed a low incidence of non-zoster opportunistic infections and direct leukemic involvement.

Conclusions:

  • The overall rate of neurologic complications in B-CLL is low.
  • Rai stage is the most significant factor correlating with the risk of neurologic complications.
  • The risk of non-zoster neurologic complications in early-stage B-CLL is approximately 1 in 1,000.

Related Concept Videos